Cost ‐effectiveness of treating wet age‐related macular degeneration at the Kuopio University Hospital in Finland based on a two‐eye Markov transition model

ConclusionA two‐eye Markov transition model was developed to analyse the cost‐effectiveness of wet AMD treatment, as quality of life years (QALYs) are largely based on the visual acuity of the better‐seeing eye. Monthly injected bevacizumab was the most cost‐effective treatment and monthly ranibizumab the least effective.
Source: Acta Ophthalmologica - Category: Opthalmology Authors: Tags: Original Article Source Type: research